DocMorris AG (ZRSEF) Q2 2026 Earnings Call Transcript

DocMorris reported H1 2026 Rx growth of 38%, accelerating to 46% in Q2, alongside a +1.1m YoY increase in active customers to 12.9m (with TeleClinic contributing 1.5m active users). Digital Services grew 71% in H1 and 80% in Q2, driving a profit lift on high margins, while management said its AI-First strategy is on track for a positive earnings contribution in H2 2026 and >CHF 15m in recurring annual net savings by end-2027. The company also raised full-year 2026 financial guidance on the back of strong commercial momentum.

Analysis

The investable point is not the top-line beat itself; it is that mix is shifting toward repeat, high-margin health services, which can re-rate the equity from a pure growth story into an operating-leverage story. If that mix persists, each incremental unit of volume should convert to disproportionately more EBITDA, and the market may start capitalizing earnings rather than revenue. The catch is that this only works if customer acquisition cost and fulfillment intensity stay contained; otherwise the company is just buying growth and delaying profitability.

Near term, the stock is most vulnerable to a classic post-earnings gap-and-fade if investors front-run the guidance raise without waiting for evidence in the next trading update. Over 1-3 months, the key catalyst path is whether weekly/monthly prescription momentum and digital-services attach rates remain elevated; that will determine whether the guide increase is a one-off or the start of a durable upward revision cycle. The main falsifier is any sign that margin uplift is being offset by heavier promo spend or operating cost inflation.

The contrarian miss is that AI is probably not the thesis; it is a support to an already-improving unit economics profile. If management can actually convert the claimed savings into recurring SG&A leverage, the longer-dated upside is multiple expansion on a cleaner FCF path. But if the savings are mostly accounting optics while competitive intensity rises, the market will keep valuing the name like a cash-burning e-commerce platform rather than a scaled healthcare compounder.

Key Decisions for Investors

• Tactically buy ZRSEF on any 3-5% post-call pullback over the next 1-2 sessions; this is a momentum trade, not a core hold, with upside to a 10-15% re-rating if the next trading update confirms the current run-rate.
• If liquidity allows, use a 1-3 month call spread on ZRSEF instead of outright stock to express the post-guidance upside while limiting downside if the gap fades; target roughly 2:1 reward/risk.
• Set a hard alert on the next disclosure for gross margin, marketing intensity, and free-cash-flow conversion; if those do not improve alongside growth, take profits quickly because the market will reclassify this as expensive growth.
• Do not force a trade in BCS or DB; there is no direct read-through and the signal belongs in ZRSEF and European e-pharmacy/telehealth peers.